Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-158 pembrolizumab in advanced solid tumors
2015-002067-41Phase 2Active
- Sponsor
- Merck & Co.
- Start
- Oct 2015
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in advanced nonhematological malignancy, anal squamous cell carcinoma (SCCA), biliary adenocarcinoma and 2 more, sponsored by Merck & Co. Primary endpoint: Objective response rate. Started Oct 2015; status: active.
02
Drugs
03
Conditions
advanced nonhematological malignancyanal squamous cell carcinoma (SCCA)biliary adenocarcinomaapudoma (NET)endometrial cancer (EC)
Beyond the preview
Go deeper on 2015-002067-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002067-41.